vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.

TRANSCONTINENTAL REALTY INVESTORS INC is the larger business by last-quarter revenue ($12.1M vs $7.2M, roughly 1.7× Arcturus Therapeutics Holdings Inc.). On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -68.4%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.

ARCT vs TCI — Head-to-Head

Bigger by revenue
TCI
TCI
1.7× larger
TCI
$12.1M
$7.2M
ARCT
Growing faster (revenue YoY)
TCI
TCI
+70.6% gap
TCI
2.3%
-68.4%
ARCT
Faster 2-yr revenue CAGR
TCI
TCI
Annualised
TCI
0.7%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
TCI
TCI
Revenue
$7.2M
$12.1M
Net Profit
$8.3M
Gross Margin
Operating Margin
-28.9%
Net Margin
68.8%
Revenue YoY
-68.4%
2.3%
Net Profit YoY
3.1%
7577.8%
EPS (diluted)
$0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
TCI
TCI
Q4 25
$7.2M
$12.1M
Q3 25
$17.2M
$12.8M
Q2 25
$28.3M
$12.2M
Q1 25
$29.4M
$12.0M
Q4 24
$22.8M
$11.8M
Q3 24
$41.7M
$11.6M
Q2 24
$49.9M
$11.8M
Q1 24
$38.0M
$11.9M
Net Profit
ARCT
ARCT
TCI
TCI
Q4 25
$8.3M
Q3 25
$-13.4M
$724.0K
Q2 25
$-9.2M
$169.0K
Q1 25
$-14.1M
$4.6M
Q4 24
$-30.0M
$108.0K
Q3 24
$-6.9M
$1.7M
Q2 24
$-17.2M
$1.5M
Q1 24
$-26.8M
$2.5M
Operating Margin
ARCT
ARCT
TCI
TCI
Q4 25
-28.9%
Q3 25
-96.3%
-10.9%
Q2 25
-41.0%
-6.8%
Q1 25
-57.3%
-5.3%
Q4 24
-146.7%
-14.3%
Q3 24
-25.8%
-14.4%
Q2 24
-42.4%
-9.2%
Q1 24
-80.0%
-11.2%
Net Margin
ARCT
ARCT
TCI
TCI
Q4 25
68.8%
Q3 25
-78.4%
5.6%
Q2 25
-32.4%
1.4%
Q1 25
-47.9%
38.5%
Q4 24
-131.8%
0.9%
Q3 24
-16.6%
14.7%
Q2 24
-34.5%
12.7%
Q1 24
-70.5%
21.4%
EPS (diluted)
ARCT
ARCT
TCI
TCI
Q4 25
$0.97
Q3 25
$-0.49
$0.08
Q2 25
$-0.34
$0.02
Q1 25
$-0.52
$0.53
Q4 24
$-1.10
$0.01
Q3 24
$-0.26
$0.20
Q2 24
$-0.64
$0.17
Q1 24
$-1.00
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
TCI
TCI
Cash + ST InvestmentsLiquidity on hand
$230.9M
$89.0M
Total DebtLower is stronger
$210.8M
Stockholders' EquityBook value
$214.0M
$846.7M
Total Assets
$271.1M
$1.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
TCI
TCI
Q4 25
$230.9M
$89.0M
Q3 25
$180.4M
$82.7M
Q2 25
$196.5M
$73.5M
Q1 25
$216.9M
$88.6M
Q4 24
$237.0M
$99.7M
Q3 24
$237.2M
$131.6M
Q2 24
$260.3M
$127.5M
Q1 24
$288.4M
$130.8M
Total Debt
ARCT
ARCT
TCI
TCI
Q4 25
$210.8M
Q3 25
$223.5M
Q2 25
$212.4M
Q1 25
$198.2M
Q4 24
$181.9M
Q3 24
$180.3M
Q2 24
$177.4M
Q1 24
$178.3M
Stockholders' Equity
ARCT
ARCT
TCI
TCI
Q4 25
$214.0M
$846.7M
Q3 25
$224.6M
$838.4M
Q2 25
$231.1M
$837.7M
Q1 25
$233.8M
$837.3M
Q4 24
$241.0M
$832.3M
Q3 24
$261.9M
$832.2M
Q2 24
$258.6M
$830.4M
Q1 24
$264.0M
$828.9M
Total Assets
ARCT
ARCT
TCI
TCI
Q4 25
$271.1M
$1.1B
Q3 25
$282.3M
$1.1B
Q2 25
$309.3M
$1.1B
Q1 25
$331.8M
$1.1B
Q4 24
$344.1M
$1.1B
Q3 24
$370.7M
$1.1B
Q2 24
$388.6M
$1.0B
Q1 24
$418.8M
$1.0B
Debt / Equity
ARCT
ARCT
TCI
TCI
Q4 25
0.25×
Q3 25
0.27×
Q2 25
0.25×
Q1 25
0.24×
Q4 24
0.22×
Q3 24
0.22×
Q2 24
0.21×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
TCI
TCI
Operating Cash FlowLast quarter
$-74.3M
$-2.9M
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
-0.35×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
TCI
TCI
Q4 25
$-74.3M
$-2.9M
Q3 25
$-17.2M
$8.2M
Q2 25
$-5.8M
$-2.9M
Q1 25
$-35.1M
$-7.4M
Q4 24
$-284.0K
$1.3M
Q3 24
$-23.8M
$13.7M
Q2 24
$-30.1M
$-511.0K
Q1 24
$-5.6M
$3.9M
Free Cash Flow
ARCT
ARCT
TCI
TCI
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
FCF Margin
ARCT
ARCT
TCI
TCI
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
Capex Intensity
ARCT
ARCT
TCI
TCI
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
Cash Conversion
ARCT
ARCT
TCI
TCI
Q4 25
-0.35×
Q3 25
11.28×
Q2 25
-17.24×
Q1 25
-1.61×
Q4 24
12.13×
Q3 24
8.03×
Q2 24
-0.34×
Q1 24
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons